NATURA-BISSÉ
Natura Bissé & Arch Amenities Group Europe have announced a formal collaboration to increase their collective presence in the luxury spa sector across the EU and the United Kingdom. The agreement fosters strategic and complementary growth opportunities for both brands, which will reference each other, capitalizing on the well-established reputation of the Natura Bissé brand, its professional and retail skincare products and services and Arch Amenities Group’s experience in managing and operating pre-eminent luxury wellness centers and spas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231122952800/en/
Barry Goldstein, CEO Arch Amenities Group (Photo: Natura Bissé)
The Spanish skincare firm, Natura Bissé, currently has a presence in more than 450 spa hotels around the world—35% of which are located in Europe—and is set to close the year with a total revenue of 100 million euros. With its headquarters in Barcelona, 82% of the company’s sales are recorded abroad, with the Unites States and China being its primary markets, followed by Spain. Over the next 3 years, Europe will become the company’s strategic focus with the aim of doubling its multi-channel presence in this region.
For its part, Arch Amenities Group and its 3800 employees currently manage over 430 properties around the world. Private clubs, fitness centers, commercial and residential spaces and, of course, hotels place their trust in the Group’s extensive experience. Among the hotel groups in their portfolio of clients are big names like Waldorf Astoria, Four Seasons and The Ritz-Carlton, who are also partners of Natura Bissé across the world.
Natura Bissé has been part of Arch Amenities Group’s Preferred Vendor Program since early 2023, connecting the Natura Bissé product suite to a host of renowned U.S.-based spas and wellness spaces such as the Eden Roc Miami Beach Resort or the Waldorf Astoria Washington DC.
Today this partnership adopts a new character as a “non-exclusive strategic agreement” in Europe, at a time when the hospitality sector is seeing increased demand for elevated wellness experiences. Proof of this comes from data in a recent report from the Global Wellness Institute, which highlights consistent 12% annual growth in the wellbeing market since 2020 and forecasts a further 52% growth by 2027.
“This strategic agreement represents a step-change in the way both leading brands address the changing needs of the European market and reinforces our collective commitment to offer unlimited innovation, inspiration as a pillar of growth and bespoke agile solutions. That is why I’m convinced that our collaboration with Arch Amenities Group Europe will allow us to expand our presence in first-class spas and wellbeing centers,” says Verónica Fisas, CEO at Natura Bissé Group.
“Partnering with Natura Bissé in Europe to develop spas is an ideal fit for Arch as we grow our presence in Europe. As one of the most celebrated luxury skincare brands in the world, our strategic collaboration with Natura Bissé allows us to extend our proven expertise in developing and managing luxury wellness spaces to bring guests an unparalleled experience powered by great products, outstanding hospitality and elevated service,” says Barry Goldstein, CEO at Arch Amenities Group.
ABOUT ARCH AMENITIES GROUP
Arch Amenities Group, based in Rockville, Maryland, is a leading provider of hospitality management and consulting services for commercial and residential properties, hotels, spas and private clubs and recreation spaces worldwide. Arch provides daily management services as well as feasibility studies, planning and design consultancy as well as recruiting, pre-opening and sustaining strategy and support. Arch is a portfolio company of private equity firm CI Capital Partners.
ABOUT NATURA BISSÉ
Natura Bissé is a globally renowned luxury skincare company. Founded in Barcelona in 1979, Natura Bissé fuses pioneering technology with the most delicate human touch in order to listen and adapt to the differing needs of each and every client.
The constant pursuit of excellence has earned Natura Bissé numerous awards, notably recognition for being the “World’s Best Spa Brand” for four consecutive years (2018-2021).
With presence in 40 countries, Natura Bissé continues to expand around the world throughout the most distinguished luxury retailers and best-in-class spas.
In 2008 the brand helped establish the Ricardo Fisas Natura Bissé Foundation to contribute to the well-being of people in vulnerable situations. To support the Foundation’s initiatives, Natura Bissé has three fundraising lines of hotel toiletries.
Images available here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231122952800/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom